samedan logo
 
 
spacer
home > pmps > spring 2004 > challenges and trends of primary packaging solutions
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Challenges and Trends of Primary Packaging Solutions

The expectations of the pharmaceutical industry with regard to primary packaging solutions for injectables have increased dramatically in recent years. Higher quality products that provide protection for valuable medications are currently in demand. Safety and ease of use for the patient, but also efficiency of the drug filling and packaging processes, are key criteria that must be met. Modern production technology, process optimisation and cost-efficiency on the one hand, health care reforms, the harmonisation of regulations and application trends on the other hand, are some of the developments that have created new challenges for manufacturing of parenteral packaging made of tubing glass.

Ampoules for High-Performance Machinability

The market for ampoules is calling for higher quality products, and several leading pharmaceutical firms that export to highly developed markets, such as Japan, have increased their requirements. The pharmaceutical market demands the highest possible safety for consumers who use ampoules, which means that process capability and process stability of the pharmaceutical company has to be optimised with top-quality ampoules.

From an end user perspective, it is important that ampoules are easy to open with maximum comfort, and more attention is now being given to the needs of new and inexperienced users. Whereas doctors and pharmacists were previously the pharmaceutical industry's primary contacts, self-medication has been playing a greater role for consumers in recent years; this has been reinforced by health care reforms in several different countries. As a result, product safety is taking on greater importance than ever before.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Olivier Leprince, Plant Manager, and Hans Peter Manser, Marketing and Sales Manager at SCHOTT

Olivier Leprince has been Plant Manager at SCHOTT France in Pont-sur-Yonne since 2001. Prior to this position, he was involved in production management for several SCHOTT plants in France over 20 years. In 2002, Olivier Leprince was also appointed TopLine Project Manager for the launch of the new product line.

Hans Peter Manser has a technical background with a buqsiness degree, completed by marketing and general management training at the IMD in Lausanne, Switzerland. He has held positions in R&D, technical support engineering, marketing and sales, with international sales and management experience, including long-term assignments in six countries worldwide. In May 2002, he became a member of the management team of SCHOTT forma vitrum, St Gallen, Switzerland and is responsible for marketing and sales.
spacer
Olivier Leprince
spacer
spacer
spacer
Hans Peter Manser
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Ubiquigent celebrates milestone anniversary of DUBprofiler™ compound profiling platform

 Dundee, UK, 14th December 2021 – Today, Ubiquigent Limited (Ubiquigent) celebrates the 10th anniversary of its DUBprofiler™ compound profiling platform, together with KSQ Therapeutics joining its expanding customer base.
More info >>

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement